Hookipa Pharma
HOOKIPA Pharma Inc. [HOOK] is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on a proprietary arenavirus platform that is designed to reprogram the body’s immune system.
Hookipa uses its non-replicating and replicating technologies to elicit directly within patients a powerful and durable response of antigen-specific killer T cells and antibodies, thereby activating essential immune defenses against infectious diseases and cancers. The company's platform technology is based on engineering arenaviruses to carry and deliver virus-specific or tumor-specific genes to dendritic cells, which are natural activators of killer T cells, also known as cytotoxic T cells, or CD8+ T cells.
Sector
Biopharmaceuticals
Strategy
Capital
Status
Live
Website
www.hookipapharma.com
Related News
HOOKIPA’s Gilead Sciences Collaboration for HIV and HBV Therapeutic Vaccines Advancing Towards Clinical Entry
HOOKIPA Pharma Announces Pricing of Initial Public Offering
HOOKIPA Pharma Raises $37.4 million (€33.2 million) in Series D Financing
HOOKIPA Appoints Michael A. Kelly as Independent Director
Hookipa Achieves First Research Milestone in HIV Collaboration and License Agreement with Gilead
HOOKIPA Appoints Julie O’Neill as a Non-Executive Director
Hookipa and Gilead Enter Into A Collaboration And License Agreement To Develop Immunotherapies Against HIV And Hepatitis B
Hookipa Biotech Raises $60 million (€50 million) in an Oversubscribed Round C Financing
Dr. Jan van de Winkel Joins Hookipa as Chairman of its Board of Directors
Hookipa Biotech presents positive data from Phase 1 first-in-human trial of vaccine against cytomegalovirus
Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa Biotech
Jörn Aldag Appointed CEO of Hookipa Biotech
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.